eFFECTOR Therapeutics- Warrants (26/08/2026) Operating Income

As of the most recent data (June 2026), EFTRW shows a operating income of $-770K. That compares with $-25M in the prior-year period — up 97.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EFTRW's operating income is now $-770K (was $-25M) — a 97.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether eFFECTOR Therapeutics- Warrants (26/08/2026) is outperforming or lagging.

Tracking EFTRW's operating income over time shows whether eFFECTOR Therapeutics- Warrants (26/08/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $-770K That compares with $-25M in the prior-year period — up 97.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has eFFECTOR Therapeutics- Warrants (26/08/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-770K) with ownership activity and broader fundamentals.

eFFECTOR Therapeutics- Warrants (26/08/2026)'s operating income is $-770K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.